Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Shifting Paradigms in the Management of Pulmonary Hypertension.
Eur Cardiol
December 2024
Department of Respiratory Medicine, King George's Medical University Lucknow, Uttar Pradesh, India.
Pulmonary arterial hypertension (PAH) is a long-term condition characterised by increased resistance to blood flow in the pulmonary circulation. The disease has a progressive course and is associated with a poor prognosis. Without treatment, PAH is associated with mortality in <3 years.
View Article and Find Full Text PDFSubmaximal versus aggressive angioplasty with drug-coated balloons for symptomatic intracranial arterial stenosis.
J Neurointerv Surg
January 2025
Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Background: Drug-coated balloons (DCB) can decrease the incidence of restenosis in the treatment of intracranial atherosclerotic stenosis (ICAS). This study aimed to assess the safety and efficacy of submaximal angioplasty with DCB dilation compared with aggressive angioplasty in patients with symptomatic ICAS.
Methods: This study prospectively and consecutively enrolled patients with symptomatic ICAS who underwent DCB angioplasty between January 2021 and December 2023.
Rationale and Design of the Prevail Global Trial Program Evaluating the Prevail Drug-Coated Balloon in Patients with In-stent Restenosis and De Novo Small Vessel Disease.
Am Heart J
January 2025
Clinical and Experimental Interventional Cardiology, University of Saarland, Homburg, Germany.
Background And Rationale: In-stent restenosis (ISR) remains the leading cause of treatment failure following percutaneous coronary intervention (PCI) with contemporary drug-eluting stents. Especially in small caliber coronary arteries, restenosis is common following PCI and represents a treatment challenge. Drug-coated balloons (DCB) are an attractive alternative to stents for treatment of both ISR and small vessel disease.
View Article and Find Full Text PDFEndoscopic Management of Benign Pancreaticobiliary Disorders.
J Clin Med
January 2025
Division of Gastroenterology and Hepatology, Center for Digestive Health, Virginia Mason, Franciscan Health, Seattle, WA 98101, USA.
Endoscopic management of benign pancreaticobiliary disorders encompasses a range of procedures designed to address complications in gallstone disease, choledocholithiasis, and pancreatic disorders. Acute cholecystitis is typically treated with cholecystectomy or percutaneous drainage (PT-GBD), but for high-risk or future surgical candidates, alternative decompression methods, such as endoscopic transpapillary gallbladder drainage (ETP-GBD), and endoscopic ultrasound (EUS)-guided gallbladder drainage (EUS-GBD), are effective. PT-GBD is associated with significant discomfort as well as variable adverse event rates.
View Article and Find Full Text PDFReal-World 12-Month Outcomes with Sirolimus-Coated Balloon Angioplasty for Complex Femoropopliteal Disease.
J Clin Med
January 2025
Department of Vascular and Endovascular Surgery, Rhein Main Vascular Center, Asklepios Clinics Langen, Paulinen Wiesbaden, 63225 Langen, Germany.
: Sirolimus-coated balloons (SCBs) have emerged as a promising alternative to paclitaxel-coated devices for the treatment of femoropopliteal lesions. However, real-world data on SCB performance in also complex peripheral arterial disease remains unknown. We sought to evaluate the safety and 12-month clinical outcomes of the Selution SLR™ balloon angioplasty in a challenging real-world patient cohort.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!